Stay updated with breaking news from Rogerm Perlmutter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tagari joins insitro from Amgen, where he led the discovery of multiple important new therapies across therapeutic areas and modalities for more than two decadesSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced that Philip Tagari...
The FINANCIAL -- Merck, known as MSD outside the United States and Canada, on August 18 announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy. The FINANCIAL -- Merck, known as MSD outside the United States and Canada, on August 18 announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical ...
Eikon Therapeutics closes $148M financing to develop super-resolution microscopy 06 May 2021 California-based firm to integrate advanced optics, machine learning with biochemistry; its target application is drug discovery. Eikon focuses on live-cell super-resolution microscopy for drug discovery.Eikon Therapeutics, a Hayward, California-based company focused on live-cell super-resolution microscopy and engineering for drug discovery, has this week announced that it has closed a $148 million Series A financing round. The funding is led by The Column Group with participation from Foresite Cap...
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19 Merck known as MSD outside the United States and Canada, today announced it has entered into an agreement with the United States Government to support the development, manufacture and initial distribution of an investigational biological therapeutic upon approval or Emergency Use Authorization from the U.S. Food and Drug Administration . Merck acquired MK-7110 through the acquisition of OncoImmune, a privately held, … ...